Dr. François R. Martelet, MD MBA, Senior Advisor at Ennovance Capital.
He is currently the Chief Executive Officer of TopoTarget, which is a biopharmaceutical company in Copenhagen that is engaged in the research and development of cancer treatments. Previously, he was President & CEO of Avax Technologies Inc., a US-based biotechnology company that specialized in the development of autologous cell vaccine for melanoma cancer patients.
Dr. Martelet worked for Merck & Co (Revenue over $23 billion/yr.) as a Vice President & Global Franchise Head and the Senior Vice President & Region Pharma Head with Novartis AG (Revenue over $42 billion/yr.). In this role, he had direct P&L responsibility (over $1 billion business) and led a team of 3,000 people within Central Europe, the Middle East, and Africa.
He previously worked as a Vice President & InterContinental Region Head of Oncology at Novartis. Under his leadership, these regions were among Novartis’ fastest growing, consistently exceeding both near and medium term profitable sales growth objectives.
Dr. Martelet received a Doctorate in Medicine and a Master's Degree in Business from Dijon University in France.
He also holds a Degree in Legal Medicine from R. Descartes University School of Medicine in Paris, France. In addition, he attended the Advanced General Management Program at INSEAD in France as well as several Senior Executive Programs at Harvard Business School.